Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5955372 | 0.92 | KMT2A (0.45) | SMOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5954445 | 0.92 | KMT2A (0.45) | SMOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5954554 | 0.85 | LTA4H (0.50) | SMOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5954521 | 0.85 | SMO (0.51) | SMOMEN1KMT2APOLBRAB9A | |
| SCHEMBL5955264 | 0.83 | KMT2A (0.43) | SMOMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL5955334 | 0.77 | NPC1 (0.47) | SMOMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL5955227 | 0.77 | NPC1 (0.47) | SMOMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL6702073 | 0.75 | RAD51 (0.49) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL5955006 | 0.75 | MGLL (0.50) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL6167661 | 0.74 | SMO (0.46) | SMOMEN1KMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LABORATOIRES FOURNIER S.A. (FR) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LIPC, CYP4F2, SLC5A2 | SMO 3766/4885MEN1 3372/4885KMT2A 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.